Clinical Trial Update: A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM [Phase 2]

View source ↗

Summary

Phase 2 study evaluating HT-6184 in combination with semaglutide for obese participants with type 2 diabetes has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• HT-6184
• semaglutide (semaglutide)

Snippet

Sponsor: Halia Therapeutics, Inc. | Conditions: Diabetes Mellitus, Type 2, Obesity | Phase 2 | Status: WITHDRAWN